BI
CDTX

BVF Inc’s Cidara Therapeutics CDTX Stock Holding History

BVF Inc’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,414,165
Closed -$135M – 42
2025
Q3 		$135M Buy
1,414,165
+627,773
+80% +$40.1M 5.49% 5
2025
Q2 		$38.3M Sell
786,392
-138,250
-15% -$3.32M 1.37% 16
2025
Q1 		$19.9M Sell
924,642
-168,154
-15% -$3.74M 0.81% 23
2024
Q4 		$29.4M Buy
1,092,796
+389,731
+55% +$6.33M 1% 23
2024
Q3 		$7.56M Buy
703,065
+360,010
+105% +$4.32M 0.22% 38
2024
Q2 		$4.1M Sell
343,055
-1
-0% -$14 0.11% 45
2024
Q1 		$6.31M Hold
343,056
– – 0.17% 44
2023
Q4 		$5.45M Hold
343,056
– – 0.14% 54
2023
Q3 		$6.46M Hold
343,056
– – 0.17% 51
2023
Q2 		$7.75M Hold
343,056
– – 0.22% 47
2023
Q1 		$8.71M Hold
343,056
– – 0.32% 52
2022
Q4 		$5.19M Hold
343,056
– – 0.22% 59
2022
Q3 		$4.31M Hold
343,056
– – 0.18% 61
2022
Q2 		$3.35M Hold
343,056
– – 0.16% 63
2022
Q1 		$5.71M Hold
343,056
– – 0.23% 65
2021
Q4 		$8.71M Buy
343,056
+104,211
+44% +$3.24M 0.32% 56
2021
Q3 		$10.7M Buy
238,845
+21,500
+10% +$817K 0.42% 52
2021
Q2 		$8.78M Buy
217,345
+30,360
+16% +$1.28M 0.33% 53
2021
Q1 		$9.95M Hold
186,985
– – 0.37% 49
2020
Q4 		$7.48M Sell
186,985
-1,350
-0.7% -$67.1K 0.29% 49
2020
Q3 		$10.7M Buy
188,335
+3,875
+2% +$274K 0.58% 43
2020
Q2 		$13.6M Sell
184,460
-6,806
-4% -$441K 0.84% 34
2020
Q1 		$9.49M Buy
191,266
+56,879
+42% +$3.41M 0.88% 28
2019
Q4 		$10.3M Hold
134,387
– – 0.78% 31
2019
Q3 		$5.36M Buy
134,387
+1,742
+1% +$58.6K 0.56% 43
2019
Q2 		$4.46M Buy
132,645
+47,111
+55% +$1.96M 0.49% 46
2019
Q1 		$4.53M Sell
85,534
-59,700
-41% -$3.27M 0.51% 44
2018
Q4 		$6.83M Buy
145,234
+48,700
+50% +$3.48M 0.89% 34
2018
Q3 		$8.49M Hold
96,534
– – 0.75% 38
2018
Q2 		$10M Buy
+96,534
New +$9.11M 0.98% 28

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BVF Inc's CDTX Position: Q4 2025 in Review

BVF Inc sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 1,414,165 shares — an estimated $135M sold.

BVF Inc first reported a position in CDTX in Q2 2018 and held it in 30 quarters. The position peaked at $135M in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

  • BVF Inc reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
  • BVF Inc sold 1,414,165 Cidara Therapeutics shares in Q4 2025, an estimated $135M.
  • BVF Inc first reported a position in Cidara Therapeutics in Q2 2018 and held it in 30 quarters.
  • BVF Inc's Cidara Therapeutics position peaked at $135M in Q3 2025.
  • 255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on BVF Inc's 13F filing for Q4 2025, filed 17 Feb 2026.